International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer

NCT01252693 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

203

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Ozarelix
DRUG: Goserelin

Sponsor

Spectrum Pharmaceuticals, Inc